Molecular and in vivo phenotyping of missense variants of the human glucagon receptor
Doctors then gradually increase it so a patients body can get used to the drug, working up to a maximum dose of 2.4 milligrams a week, according to Novo Nordisk, the pharmaceutical company that makes it
Both naturally decline with age
Dillon JS, Tanizawa Y, Wheeler MB, Leng XH, Ligon BB, Rabin DU, Yoo-Warren H, Permutt MA, and Boyd AE, 3rd
Bone turnover markers (such as C-terminal telopeptide and procollagen type 1 N-terminal propeptide) may provide earlier signals of altered bone metabolism, though their routine use is not standard practice in general clinical settings
The required beta cell research for improving treatment of type 2 diabetes